jvm13  (ATCC)

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: A cyclin D1-dependent transcriptional program predicts clinical outcome in mantle cell lymphoma

doi: 10.1158/1078-0432.CCR-20-2868

Figure Lengend Snippet: (A) Western blot analysis of cyclin D1 in control (shCtrl) and cyclin D1-silenced (shCycD1 #1 and #2) MCL cell lines. Tubulin was used as loading control. Cyclin D1 quantification normalized by tubulin and relative to shCtrl cells is shown. Molecular weights (in kDa) are indicated. (B) RNA-seq experiment in shCtrl and shCycD1 #1 MCL cells. Left, heatmaps showing significantly upregulated (red) and downregulated (green) genes in the three biological replicates. Right, Venn diagrams showing the overlap between differentially expressed genes in Granta-519 (G) and JeKo-1 (J) cells (in bold), which were selected for further analysis. (C) Venn diagrams showing the overlap between either upregulated (red) or downregulated (green) genes in shCycD1 MCL cells and cyclin D1 (CycD1) target genes by ChIP-seq in four MCL cell lines (n = 8,638). Statistical significance was assessed by one-tailed Fisher’s test. (D) Differential expression analysis of the cyclin D1-activated genes identified in MCL cells (n = 448) in CycD1wt or CycD1T286 overexpressing versus control JVM13 cells.

Article Snippet: Cell lines We used two well characterized MCL cell lines ( 13 ), JeKo-1 (ATCC, CRL-3006, RRID:CVCL_1865) and Granta-519 (DSMZ, ACC-342, RRID:CVCL_1818), the lymphoblastoid leukemic cell line JVM13 (ATCC, CRL-3003, RRID:CVCL_1318), and HEK293T (ATCC, CRL-3216, RRID:CVCL_0063).

Techniques: Western Blot, Control, RNA Sequencing, ChIP-sequencing, One-tailed Test, Quantitative Proteomics

Journal: Antibody therapeutics

Article Title: Generation of antibody-based therapeutics targeting the Idiotype of B-cell Malignancies.

doi: 10.1093/abt/tby012

Figure Lengend Snippet: Binding and cytotoxity of immunotoxins for B-cell tumor lines. The scFvs of Binder 1 and 7 phage were cloned into a toxin vector (PE38) to make single chain immunotoxins. A. Binding to MEC1 cells was confirmed by flow cytometry using and antibody to the toxin. Unstained and anti-toxin controls are shown in red and orange. Binder-1 (left) and binder-7 (right) histograms are shown in light blue. Binder1-scFv-PE38 and Binder7-scFv-PE38 (5, 50, 500 and 5000 ng/ml) were incubated with B. MEC1. C. JVM13 or D. Nalm6 cells. The immunotoxin HA22, directed to CD22 was used as a positive control. Viability was determined after 72 hr using the CellTiter-Glo® assay to measure ATP levels.

Article Snippet: JVM13 cells were purchased from ATCC.

Techniques: Binding Assay, Clone Assay, Plasmid Preparation, Flow Cytometry, Incubation, Positive Control, Glo Assay

Journal: Antibody therapeutics

Article Title: Generation of antibody-based therapeutics targeting the Idiotype of B-cell Malignancies.

doi: 10.1093/abt/tby012

Figure Lengend Snippet: Binding of ‘binder 1’ monoclonal antibody to cells. A. Binding to MEC1 cells and B. binding to JVM13 cells. MORAb-009 antibody, also an IgG1, (reactive with surface mesothelin on epithelial tumors) was used as an isotype control. Red=no primary antibody. Blue=isotype control. Green=Binder 1 antibody.

Article Snippet: JVM13 cells were purchased from ATCC.

Techniques: Binding Assay, Control